drugset / Trial / NCT01257594
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
Phase 1
Completed
22 enrolled
Andrew B Lassman, MD
Genentech, Inc. · collabOSI Pharmaceuticals · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to test the effectiveness of a drug called erlotinib in treating the tumor. This is a multi-center pilot study that explores efficacy and molecular effects of high dose weekly erlotinib for recurrent EGFR vIII mutant malignant gliomas, and correlate molecular profile of pre-treatment tissue with outcome.
Timeline
- Start
- 2011-01-07
- Primary completion
- 2016-11-22
- Completion
- 2018-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 2000 mg | Oral |